US National Institutes of Health cancels HIV vaccine trialBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a926 (Published 21 July 2008) Cite this as: BMJ 2008;337:a926
- Bob Roehr
- 1Washington, DC
The US National Institutes of Health is cancelling the largest, most complicated HIV vaccine trial yet envisaged. The 17 July decision is the culmination of 10 months of meetings and discussions after the stopping of a Merck HIV vaccine trial last September.
The Vaccine Research Center at the National Institutes of Health developed the vaccine for the PAVE (partnership for AIDS vaccine evaluation) 100 trial. The trial was supposed to have started last autumn, involving 8500 participants on three continents, but was put on hold …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial